Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 2.6% and the Health Care Select Sector SPDR Fund (XLV) dropping 2.7%.
The iShares Biotechnology ETF (IBB) slumped 5.7%.
In sector news, the US Food and Drug Administration said Tuesday it plans to expand its use of surprise inspections at foreign facilities that make food, essential medicines, and other medical products for US consumers.
In corporate news, NuCana (NCNA) shares tumbled 66% after it priced a $7 million registered direct offering.
Heron Therapeutics (HRTX) shares jumped past 13% after the firm said it reached a settlement agreement with Viatris' (VTRS) Mylan Pharmaceuticals to resolve patent litigation over the Cinvanti and Aponvie injectable emulsions. Viatris lost 0.8%.
Beam Therapeutics (BEAM) shares tumbled nearly 20% after it reported a wider Q1 loss compared with a year earlier.
Philips (PHG) shares fell 5.9% after it reported flat Q1 adjusted earnings per share, while sales declined.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.